BDNF comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Due to its extremely long half-life, 209Bi can be treated as non-radioactive for nearly all applications. It is much less radioactive than human flesh, so it poses no real radiation hazard. Though 209Bi holds the half-life record for alpha decay, it does not have the longest known half-life of any nuclide; this distinction belongs to tellurium-128 (128Te) with a half-life estimated at 7.7×1024 years by double beta decay. The half-life of 209Bi was confirmed in 2012 by an Italian team in Gran Sasso who reported (2.01±0.08)×1019 years. They also reported an even longer partial half-life for alpha decay of 209Bi to the first excited state of 205Tl (at 204 keV), estimated at 1.66×1021 years. Even though this value is shorter than the half-life of 128Te, both alpha decays of 209Bi hold the record of the thinnest natural line widths of any measurable physical excitation, estimated respectively at ΔΕ ≈ 5.5×10−43 eV and ΔΕ ≈ 1.3×10−44 eV in application of the uncertainty principle
A planned appearance August 30, 2026, at a Chapel Hill nightclub was canceled following plans for community protests. In July 2026, The New York Times listed Peters as one of the most stylish people of 2026.
1973); British-Israeli politician, media expert, journalist, media-spokesperson, policy maker; Deputy Mayor of Jerusalem in charge of foreign relations, international economic development and tourism; co-founder of UAE–Israel Business Council; appointed by Israel's foreign minister Eli Cohen as special envoy for innovation; has written editorials, commentary, and op-ed columns for The Telegraph, Jerusalem Post, La Voz de Galicia, Times of Israel, Haaretz, Ynet News, Gulf Business, Arutz Sheva/Israel National News, Algemeiner Journal, Jewish Journal (Los Angeles), Jewish News, JNS, Jüdische Allgemeine, Salem Radio Network News, The Media Line, The Detroit Jewish News, Jewish Policy Center, Israel Behind The News, The Jewish World, Jewish Chronicle; previously served as president of King's College Jewish Society; was barrister at Middle Temple; served as campaign director at World Jewish Relief; served as senior associate with American Jewish Joint Distribution Committee; CEO of international strategic communications firm, Message Experts; worked with U.S. State Department on embassy in Jerusalem; one of founders of UAE–Israel Business Council. Dan Neidle (b.
In one study, disk diffusion method proved concentration-dependent antifungal activity against Trichophyton, Microsporum and Epidermophyton, three of the most common species of dermatophytes that cause superficial fungal infections of human skin. Further research is needed, however, to examine the role of sangre de grado from Croton lechleri as an effective antifungal agent in animal and human models. Antiviral activity against influenza, parainfluenza, Herpes simplex viruses I and II, and Hepatitis A and B by Croton lechleri extracts and compounds have been exhibited. The most notable compound involved in antiviral activity is SP-303, also known as crofelemer, which has been heavily studied in vitro for its antiviral activity against the aforementioned viruses, as well as thymidine kinase mutants of HSV-1 and HSV-2 and acyclovir-resistant strains. Antidiarrhoeal Activity Crofelemer, a purified proanthocyanidin oligomer extracted from the sap of Croton lechleri has been investigated for potential antidiarrhoeal activity. Various clinical studies have confirmed significant improvement in acute E. coli and V. cholera diarrhea cases from the administration of crofelemer. In the context of the principal luminal membrane determinants of intestinal fluid secretion, the mechanism of crofelemer action involves the inhibition of apical membrane cAMP-stimulated (CFTR) and calcium-stimulated (CaCC) Cl− channels by crofelemer molecules, with little effect on cation channels or cAMP/calcium signaling.
=== Bacteria === Bacteria are common causes of foodborne illness. In 2000, the United Kingdom reported the individual bacteria involved as the following: Campylobacter jejuni 77.3%, Salmonella 20.9%, Escherichia coli O157:H7 1.4%, and all others less than 0.56%. In the past, bacterial infections were thought to be more prevalent because few places had the capability to test for norovirus and no active surveillance was being done for this particular agent. Toxins from bacterial infections are delayed because the bacteria need time to multiply. As a result, symptoms associated with intoxication are usually not seen until 12–72 hours or more after eating contaminated food. However, in some cases, such as Staphylococcal food poisoning, the onset of illness can be as soon as 30 minutes after ingesting contaminated food.
Sources: en.wikipedia.org
=== Operations in Russia === Dr. Reddy's Laboratories has faced significant criticism for its continued operations in Russia, despite the ongoing invasion of Ukraine and the imposition of international sanctions on the country. While many global pharmaceutical companies have ceased or drastically reduced their presence in Russia in response to the invasion, Dr. Reddy's has remained steadfast in maintaining its business there. In May 2022, the company reported a surge in sales, with revenues in Russia increasing by 70% year-over-year. The company's leadership declared that operations were continuing "as usual," and even announced plans to launch new products in the Russian market. This decision has sparked widespread ethical concerns, as Dr. Reddy's has been accused of prioritizing profits over the human suffering caused by the war. Despite the global condemnation of Russia's actions and the continued killings of civilians in Ukraine, Dr. Reddy's refusal to withdraw from Russia has raised questions about its commitment to international norms and human rights. The company has also faced backlash for its ties to the Russian Direct Investment Fund (RDIF), which has backed the Sputnik V vaccine, further complicating its position amid the conflict. By continuing operations in Russia, Dr. Reddy's is seen as contributing to the Russian economy and, by extension, supporting a regime responsible for war crimes and aggression.
==== TP0624 ==== Outer Membrane Protein A (OmpA) domain-containing proteins are necessary for maintaining structural integrity in gram-negative bacteria. These domains contain peptidoglycan binding sites which creates a "structural bridge between the peptidoglycan layer and the outer memebrane." The protein TP0624 found in T. pallidum has been proposed to facilitate this structural link, as well as interactions between outer membrane proteins and corresponding domains on the thin peptidoglycan layer.
Tirzepatide is an analog of gastric inhibitory polypeptide (GIP), a human hormone that stimulates the release of insulin from the pancreas. Tirzepatide is a linear polypeptide of 39 amino acids that has been chemically modified by lipidation to improve its uptake into cells and its stability to metabolism. It completed phase III trials globally in 2021.
=== Dependence and withdrawal === Tolerance to phenibut easily develops with repeated use, leading to dependence. Withdrawal symptoms may occur upon discontinuation, and, in recreational users taking high doses, have been reported to include severe rebound anxiety, insomnia, aggression, irritability, agitation, visual and auditory hallucinations, seizures and acute psychosis. Baclofen has successfully been used for treatment of phenibut dependence.
== Research == Poor interim results led to the abandonment of the two CHAMPION clinical trials in mid-2009. The BRIDGE study, for short term use prior to surgery, continues. The CHAMPION PHOENIX trial was a randomized study of over 11,000 patients published in 2013. It found usefulness of cangrelor in patients getting cardiac stents. Compared with clopidogrel given around the time of stenting, intravenous ADP-receptor blockade with cangrelor significantly reduced the rate of stent thrombosis and myocardial infarction. Reviewers have questioned the methodology of the trial.
Sources: en.wikipedia.org
=== Environmental pollution === Considering the complex interactions between humans, animals and the environment, it is also important to consider the environmental aspects and contributors to antimicrobial resistance. One of these factors is human and hospital waste, which is a substantial contributor to environmental antimicrobial resistance (AMR). It is estimated that around 50–80% of antibiotics are passed unmetabolized in urine and 4–30% in feces, causing large quantities of active antibiotics to enter sewage systems. Sewage environments contain high levels of antimicrobial-resistant bacteria (ARB), antimicrobial resistance genes (ARGs), and mobile genetic elements such as plasmids, which enable rapid gene exchange. Wastewater treatment plants (WWTPs) are typically not designed to remove AMR; in some cases, multidrug-resistant species such as Escherichia, Shigella, and Klebsiella can increase twofold in treated wastewater. Methicillin-resistant Staphylococcus aureus (MRSA) has also been detected in both raw and treated sewage. Agriculture is also a major contributor to environmental AMR. Manure from livestock (such as cattle, sheep, etc.) contains residual antibiotics, which enter the soil as farmers usually use it as fertilizer. These are typically at levels of 1–10 mg/kg, and also contain ARBs and ARGs. One megaton of antibiotics has been estimated to have entered global soils through manure application. Pathogens can survive in soil for up to 10 years and on plant surfaces for up to 1 year, thereby enabling long-term environmental continuation of AMR.
It efficiently sterilizes the infected root surfaces and periodontal pocket microflora Curettes the adjacent pocket epithelium Removes the smear layer Enhances calculus elimination It has been suggested that laser treatment results in minimal or no post-operative swelling, bleeding, scar tissue formation or pain. Regarding wound healing animal studies have shown better response in rat skin after Nd:YAG laser application than following scalpel incisions but this is only valid when energy and frequency parameters were low and higher levels of energy lead to scar formation and delayed wound healing. The clinical use of a laser for gingivectomy involves repeated lasing and wiping away tissue remnants with moist gauze and this results in a bloodless operating field allowing better visibility and greater ease for the operator. Apart from ablating and coagulating the laser also sterilizes the tissues and eliminates the need for a post-surgical dressing. One study found that in patients with drug induced gingival overgrowth recurrence was minimal or eliminated when comparing laser gingivectomy to scalpel gingivectomy.
=== Inefficiency and corruption === Inefficiencies and corruption in distribution systems can lead to artificial shortages and price manipulation, contributing to inflation. This situation is rooted in several systemic issues:
=== Bioremediation === Xerophilic micro organisms can be utilized in efforts of bioremediation. This is especially the case when the environment needing bioremediation has low water activity. Xerotolerant bacteria isolated from areas in Chile have expressed traits allowing it to be used as to begin bioremediation.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.